KalVista pharmaceuticals, a US-based clinical stage pharma discovery firm, released positive results from its lead oral drug candidate, KVD900, in treating hereditary angioedema (HAE). The data from the phase 2 trial in on-demand use for HAE attacks was presented at the American Academy of Allergy, Asthma & Immunology Annual Scientific Meeting, and showed that the drug suppressed plasma kallikrein activity after KVD900 administration and demonstrated its relationship with symptomatic relief. The company hopes that the drug would soon be commercialised.

Source: stockhouse.com